PUBLISHER: Grand View Research | PRODUCT CODE: 1679351
PUBLISHER: Grand View Research | PRODUCT CODE: 1679351
The global disposable prefilled syringes market size was valued at USD 7.3 billion in 2024 and is projected to grow at a CAGR of 13.7% from 2025 to 2030. This growth is driven by increasing demand for biologics, rising prevalence of chronic diseases, and the growing preference for self-administered injectable drugs. Prefilled syringes enhance patient safety, reduce contamination risks, and improve dosage accuracy, further fueling market expansion. Additionally, advancements in syringe materials, such as glass and polymer-based options, are improving product durability and usability. Expanding healthcare infrastructure and regulatory approvals for biologic therapies will further support market growth.
A significant driver of this market expansion is the escalating demand for biologic drugs, which often require precise and stable delivery systems. Biologics, including monoclonal antibodies used in the treatment of autoimmune diseases and cancers, are frequently administered via injection. For instance, AbbVie's Humira (adalimumab), a leading biologic for conditions such as rheumatoid arthritis and Crohn's disease, is available in prefilled syringe formats to ensure accurate dosing and enhance patient convenience. Similarly, Roche's Actemra (tocilizumab), used for rheumatoid arthritis and certain COVID-19-related complications, is offered in prefilled syringes to facilitate ease of administration.
The rising prevalence of chronic diseases, notably diabetes, further propels the market. According to the International Diabetes Federation, approximately 537 million adults aged 20 to 79 were living with diabetes in 2021, underscoring the need for efficient and reliable insulin delivery methods. Prefilled insulin syringes provide a safer and more convenient alternative to traditional vial-and-syringe approaches, reducing the risk of dosing errors and enhancing patient compliance.
Another contributing factor is the growing trend toward self-administration of injectable medications. Patients managing chronic conditions, such as multiple sclerosis and diabetes, increasingly prefer prefilled syringes for home use, minimizing the necessity for frequent healthcare facility visits. This shift is supported by the development of user-friendly syringe designs equipped with integrated safety features. For example, Sanofi's Dupixent (dupilumab), prescribed for atopic dermatitis and asthma, is available in prefilled syringes, enabling patients to self-administer their treatments effectively.
The COVID-19 pandemic has also influenced the adoption of disposable prefilled syringes, particularly in vaccination efforts. Vaccines developed by companies like Moderna and Pfizer-BioNTech have been distributed using prefilled syringes to ensure precise dosing and reduce contamination risks, highlighting the importance of such delivery systems in large-scale immunization programs.
Technological advancements in syringe materials and manufacturing processes are enhancing product safety and compatibility, especially with complex biologics. Prefilled syringes are now available in both glass and polymer formats, with polymer syringes gaining popularity due to their break resistance and reduced interaction with sensitive drugs. Leading companies like Becton, Dickinson and Company (BD) and Gerresheimer are at the forefront of innovating syringe design and production, focusing on improving drug stability and patient safety.
Global Disposable Prefilled Syringes Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global disposable prefilled syringes market report on the basis of material, application, distribution channel, and region: